12. Timms KM et coll : Association of BRCA1/2 defects with genomic scores predictive of DNA
damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014 Dec
5;16(6):475. PMID: 25475740
13. Telli ML et coll : Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant
Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With
Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol.
2015 Jun 10;33(17):1895-901. PMID: 25847929
14.
Isakoff SJ et coll : TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy
With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015
Jun 10;33(17):1902-9. PMID: 25847936
15. Popova T et coll : Ploidy and large-scale genomic instability consistently identify basal-like
breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012 Nov 1;72(21):5454-62.
PMID: 22933060
16. Peng G et coll : Genome-wide transcriptome profiling of homologous recombination DNA
repair. Nat Commun. 2014;5:3361. PMID: 24553445
17. Mulligan JM et coll : Identification and validation of an anthracycline/cyclophosphamide-
based chemotherapy response assay in breast cancer. J Natl Cancer Inst. 2014
Jan;106(1):djt335. PMID: 24402422
18. Vollebergh MA et coll : Genomic patterns resembling BRCA1- and BRCA2-mutated breast
cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res.
2014 May 15;16(3):R47. PMID: 24887359
19. Lehmann BD, Pietenpol JA : Clinical implications of molecular heterogeneity in triple
negative breast cancer. Breast. 2015 Nov;24 Suppl 2:S36-40. PMID: 26253813
20. Masuda H et coll : Differential response to neoadjuvant chemotherapy among 7 triple-
negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 1;19(19):5533-40.
PMID: 23948975
21. Safarpour D, Tavassoli FA : A targetable androgen receptor-positive breast cancer subtype
hidden among the triple-negative cancers. PMID: 25310144
22. Proverbs-Singh T et coll : Targeting the androgen receptor in prostate and breast cancer:
several new agents in development. Endocr Relat Cancer. 2015 Jun;22(3):R87-R106. PMID:
25722318
23. Traina TA et coll : Results from a phase 2 study of enzalutamide (ENZA), an androgen
receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). 2015 ASCO
Annual Meeting, J Clin Oncol 33, 2015 (suppl; abstr 1003)
24. Ben-Baruch NE et coll : HER2-Mutated Breast Cancer Responds to Treatment With Single-
Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. J Natl Compr
Canc Netw. 2015 Sep;13(9):1061-4. PMID: 26358790
25. Balko JM et coll : Molecular profiling of the residual disease of triple-negative breast
cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer
Discov. 2014 Feb;4(2):232-45. PMID: 24356096
26. Craig DW et coll : Genome and transcriptome sequencing in prospective metastatic triple-
negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013
Jan;12(1):104-16. PMID: 23171949
27. Ross JS et coll : Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-
generation sequencing reveals frequent, targetable genomic abnormalities and potential
new treatment options. PMID: 25927147
